{"id":2871,"date":"2026-09-03T13:00:00","date_gmt":"2026-09-03T17:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2871"},"modified":"2026-09-04T16:45:36","modified_gmt":"2026-09-04T20:45:36","slug":"car-t-persists-in-cerebrospinal-fluid-after-tisa-cel","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2871","title":{"rendered":"CAR-T Persists in Cerebrospinal Fluid After Tisa-cel"},"content":{"rendered":"

Institution:<\/strong> St. Jude Children’s Research Hospital · Product:<\/strong> Tisagenlecleucel (Commercial CD19 CAR-T) · Finding:<\/strong> Long-Term CSF Persistence · Population:<\/strong> Pediatric\/Young-Adult B-ALL · Date:<\/strong> September 3, 2026<\/p>\n

\"CAR-T<\/p>\n

Summary<\/h4>\n

A St. Jude longitudinal study detected tisagenlecleucel-derived CD19 CAR-T cells in cerebrospinal fluid in 28 of 29 pediatric and young-adult B-ALL patients at one month and in 41 of 49 later samples. CAR-T cells were enriched relative to total T cells in CSF and did not track with red-cell contamination, supporting true CNS persistence. Higher CSF CAR-T levels associated with higher-grade CRS or ICANS, but the study was not powered to determine whether persistence prevents CNS relapse or causes neurotoxicity.<\/p>\n

What Happened<\/h4>\n

Twenty-nine patients received standard-of-care tisagenlecleucel for relapsed or refractory B-ALL between October 2020 and January 2025. None had active CNS leukemia immediately before infusion, although 20 had a prior CNS history. Twenty-seven responded in marrow and 22 achieved MRD-negative complete remission. Serial qPCR assessed CAR transgene and TRAC copies in blood, marrow and CSF through 12 months. CAR-T cells were detected in 96.4% of one-month CSF samples and 80.5% of later samples. CSF CAR burden correlated poorly with peripheral blood, suggesting compartment-specific kinetics. Grade 2-4 CRS and ICANS were associated with higher one-month CSF CAR levels. Seven patients relapsed overall; three had CNS involvement, but the small event count and timing of sampling prevented outcome attribution.<\/p>\n

Deep Analysis<\/h4>\n

The consistent detection of CAR-T cells in a compartment that conventional antibodies penetrate poorly supports a plausible mechanism for activity against CNS B-ALL. Enrichment relative to total T cells and independence from red-cell contamination strengthen the localization claim. Counterevidence is that three CNS relapses still occurred and two were CD19-negative, indicating that antigen escape can defeat even adequate trafficking; no threshold for protective persistence was identified. Associations with more intense CRS and ICANS suggest that systemic activation can drive expansion or migration into CSF, which could make CSF CAR abundance a pharmacodynamic or safety biomarker. The alternative is reverse causality or shared dependence on systemic expansion; the study cannot show that CSF CAR-T cells directly cause neurologic toxicity, and cytokine panels did not correlate with CSF CAR levels, further limiting mechanistic interpretation.<\/p>\n

Company and Product Background<\/h4>\n

This academic study was conducted at St. Jude Children’s Research Hospital using commercially available tisagenlecleucel. Tisa-cel is an autologous CD19-directed CAR-T product in which patient T cells are collected, genetically modified ex vivo and reinfused after lymphodepletion. The CAR recognizes CD19 on malignant and normal B-lineage cells, enabling cytotoxic clearance and often producing prolonged B-cell aplasia. B-cell acute lymphoblastic leukemia is the most common childhood leukemia. The CNS can act as a pharmacologic sanctuary, and CNS-directed chemotherapy or radiation carries substantial late-effect burden. CAR-T trafficking into CSF could contribute to control of occult CNS disease, but CD19-negative escape, limited persistence and treatment-associated neurotoxicity remain important failure modes.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Cohort<\/td>\n29 pediatric\/young-adult B-ALL patients, serial CSF sampling through 12 months<\/td>\n<\/tr>\n
CSF Detection<\/td>\n96.4% at 1 month; 80.5% of later samples; enriched vs. total T cells<\/td>\n<\/tr>\n
Safety Association<\/td>\nHigher 1-month CSF CAR levels associated with grade 2-4 CRS\/ICANS<\/td>\n<\/tr>\n
Relapse<\/td>\n7 relapses; 3 CNS-involved (2 CD19-negative); event count too small for attribution<\/td>\n<\/tr>\n
Signal Type<\/td>\nFirst longitudinal CSF persistence dataset, biomarker-development stage<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Consistent, enrichment-confirmed CAR-T detection in CSF across nearly all patients through 12 months provides a plausible biological mechanism for CNS disease control in a sanctuary site that conventional antibody therapies penetrate poorly.<\/p>\n

Bear case:<\/strong> Three CNS relapses still occurred despite persistence, two of them CD19-negative, and higher CSF CAR levels tracked with more severe CRS\/ICANS, leaving open whether CSF burden reflects protective surveillance or simply systemic inflammatory activation.<\/p>\n

InSilens Take<\/h4>\n

The study turns CNS penetration from an assumed property of CD19 CAR-T into a measurable longitudinal phenomenon. Its strategic value is highest as a biomarker-development signal: CSF kinetics may help distinguish sanctuary-site surveillance from inflammatory trafficking. The data do not justify routine lumbar puncture monitoring or claims that persistence prevents CNS relapse. Prospective sampling aligned with relapse and ICANS events is needed before the observation can guide product engineering or clinical management.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Uncertain · Confidence:<\/strong> High on facts, Moderate-low on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

A St. Jude longitudinal study detected tisagenlecleucel-derived CD19 CAR-T cells in cerebrospinal fluid in 28 of 29 pediatric and young-adult B-ALL patients at one month and in 41 of 49 later samples. CAR-T cells…<\/p>\n","protected":false},"author":1,"featured_media":2877,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[202,545,168,544],"class_list":["post-2871","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-b-cell-acute-lymphoblastic-leukemia","tag-cerebrospinal-fluid","tag-st-jude-childrens-research-hospital","tag-tisagenlecleucel"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2871"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2871\/revisions"}],"predecessor-version":[{"id":2896,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2871\/revisions\/2896"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2877"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}